drugset / Trial / NCT04500756
Limiting AAA With Metformin (LIMIT) Trial
Phase 2
Recruiting
314 enrolled
Stanford University
Kaiser Permanente · collabNational Heart, Lung, and Blood Institute (NHLBI) · collabVA Palo Alto Health Care System · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
In this research, the investigators are looking at the effects of a drug called metformin may have on the growth of abdominal aortic aneurysm (AAA)s. AAA is an abnormal enlargement of the aorta, which is the large artery in the abdomen (stomach area). The enlargement of the aorta carries a risk that it will rupture and cause life-threatening bleeding in the abdomen (belly). In this study the investigators hope to learn how metformin is associated with the enlargement or change in size of the AAA in study participants. Smaller studies have suggested that metformin may reduce the rate at which aortic aneurysms enlarge. This study will test this question: does metformin prevent AAAs from growing larger?
Timeline
- Start
- 2022-02-28
- Primary completion
- 2028-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metformin | Small molecule | 2000 mg | — |